said that Anil R. Diwan, PhD, President of the Company, was a participant in
a panel on global pharmaceutical strategies at the Fourth Annual Swedish-American
Life Sciences Summit held August 20-22, 2008 in Stockholm, Sweden. Speaking
in front of a large pharmaceutical and life sciences finance industry group,
he enumerated the accomplishments of the Company. He also presented his thoughts
on the Company’s global strategy for supplying nanoviricides treatments
for serious viral diseases to both developed and developing countries.
Dr. Diwan was invited as a panel member on the panel discussion “Emerging
Life Sciences in a Global Context- A New Necessity” held last Friday.
After discussing the Company’s accomplishments, he spoke about the successes
of the nanoviricides technology. In response to a question, he said that the
Company has a strong focus on commercially important disease targets such as
Influenza, Bird Flu, viral diseases of the eye, HIV, and Hepatitis C. He added
that the Company has developed a unique broad-spectrum antiviral technology
that can work well against a large number of different viruses. Using such agents,
it will be possible to develop cost-effective treatment strategies against lethal
diseases of the developing world such as Rabies, Dengue virus, and many others.
Many of these diseases are now being seen more frequently in developed countries
The Fourth SALSS featured leaders of Life Sciences industry in both Sweden
and the United States. This forum brought together key pharmaceutical executives,
entrepreneurs, venture capitalists and financiers, and key scientists from both
countries in an invitation-only open-discussion format. (http://www.marketwatch.com/news/story/swedish-american-life
Posted August 25th. 2008